Floatz logo

5-PYRIMIDINECARBOXAMIDE, 2-((1,1-DIMETHYLETHYL)AMINO)-4-(((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYL)AMINO)-

Respiratory Tract Diseases

CelgeneSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Respiratory Tract Diseases cohort.

Asset / SponsorPhaseRating
Carboplatin
Nanfang Hospital, Southern Medical University
Phase 3BB
Rocuronium
Ziekenhuis Oost-Limburg
Phase 4BB
.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO-
Ziekenhuis Oost-Limburg
Phase 4BB
NEOSTIGMINE
Ziekenhuis Oost-Limburg
Phase 4BB
NEOSTIGMINE
Coastal Anesthesiology Consultants
Phase 4BB

View all 33 →

Same molecule, other indications

5-PYRIMIDINECARBOXAMIDE, 2-((1,1-DIMETHYLETHYL)AMINO)-4-(((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYL)AMINO)- is also rated in:

idiopathic interstitial pneumoniaDormant
CCC
Indicative ·
53 / 100
View asset →
Pathologic ProcessesDormant
CCC
Indicative ·
53 / 100
View asset →
interstitial lung diseaseDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →